At the news
? NEUTRALIMPACT 4/10 CLUSTER filed Mar 15, 2026 at 20:00 ET
Director Theresa Heggie sold 49,933 shares of BioCryst Pharmaceuticals for $504,823 in an open-market transaction. This sale was accompanied by the exercise of derivative securities related to the same share amount, including a non-cash exercise. The total open-market sale represents a modest but notable insider disposition.
- Director Theresa Heggie sold 49,933 shares at $10.11 per share for total proceeds of $504,823.
- On the same day, she exercised derivative securities for 99,866 shares (two separate exercises: one at $6.30 and one at $0 strike price).
- Only the open-market sale (Form 4 code 'S') represents a cash transaction; the derivative exercises (code 'M') are non-cash events and do not reflect new investment or direct selling pressure.
- Total open-market selling in the past 7 days: $504,823 (one insider). Recent 30-day selling totals $1.9M across two insiders.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access